Treatment of Myelin Oligodendrocyte Glycoprotein–Associated Disease

Myelin oligodendrocyte glycoprotein–associated disease (MOGAD) is increasingly recognized due to antibody testing, but no therapies have been approved (NEJM JW Neurol 2020 Jul 21 and Neurology 2020 Jul; 95:e111). To evaluate relapses on various therapies, investigators conducted this single-center, retrospective study of 88 patients with MOGAD (59 adult-onset and 29 pediatric-onset) with a median of 6.7 years' follow-up.

Compared with a pretreatment annualized relapse rate of 1.05, prednisone reduced relapses by 54%, intravenous immunoglobulin (IVIG) by 87%, 49% for B-cell depletion (BCD), and mycophenolate by 78%. Results were similar in the pediatric MOGAD subgroup.